Clinical Trials

This project aims to understand protective factors present in maternal breastmilk. We hypothesize the maternal proteins will be present in infant stool of breastmilk babies in a concentration that reflects the concentration in breastmilk. Furthermore we hypothesize the concentration of proteins in both donor milk and the stool of infants fed donor milk will be decreased when compared to age matched mom’s own milk (MOM) fed infants. We will be measuring the concentration of maternal proteins in milk and stool of infants. 

The study is being done to determine effective and ineffective advanced communication methods neonatologists use to reach decisions with families regarding the care for infants with severe life-threatening diagnoses, specifically, the non-initiation or provision of resuscitation for infants with likely very poor but uncertain prognoses for whom survival may be associated with a severely diminished quality of life. The study will also examine how parents are able to understand the information given to them by neonatologists during the prenatal consultations under conditions of emotional and physical distress and how they experience the consultation.

The purpose of this two-part Phase 2 study is to assess the safety, tolerability and efficacy of aerosolized SF-RI 1 (AeroFact) when delivered via nCPAP at two different doses.

The purpose of this study is to determine whether initiating breathing assistance prior to clamping the umbilical cord influences the occurrence of intraventricular (brain) hemorrhage in extremely preterm infants, compared to the standard care of starting ventilation assistance after cord clamping.

The purpose of this study is to identify components of the vaginal microbiology environment that contribute to the occurance of preterm labor and preterm delivery.

The primary purpose of this study is to investigate the cytokine responses of blood ILC2s from preterm children by collecting peripheral blood at age 5-10 years from children born either preterm or at term, and to analyze the functions of their circulating ILC2s in vitro.

This study is conducted to determine whether the rates of birth defects, miscarriages, premature births and other outcomes in women with inflammatory bowel disease (IBD) taking azathioprine/6MP or biologic therapy (Remicade®, Humira®, Cimzia™, Tysabri®, or Stelara®) are different from those among IBD - affected women not taking these medications.